Cleveland BioLabs

73 High St.
Buffalo, NY 14203 USA
Click for website

Research Sector Pharmaceutical

Summary Description Drugs designed to control cell death and combat cancer.

Management Yakov Kogan, Ph.D., MBA, Chief Executive Officer; Andrei Gudkov, Ph.D., D. Sci., Chief Scientific Officer; C. Neil Lyons, Chief Financial Officer; Michael Kurman, MD, Chief Medical Officer

Click here for Financial Data
Keywords: drugs, medical, cancer institute, radiobiology, protectans, curaxins


Updated: Feb. 24, 2015


Established in 2003, Cleveland BioLabs, Inc. (Nasdaq:CBLI) is a biotechnology company leveraging its proprietary discoveries around programmed cell death to develop a pipeline of drugs for multiple me......view more

Products / Services

Protectan CBLB502 for Acute Radiation Syndrome Protectan CBLB502 for supportive care in cancer treatment Protectan CBLB612 for induction and mobilization of hematopoeitic stem cells Curaxin CBLC13......view more

Technology / Differentiation

The scientific foundation of Cleveland BioLabss product development efforts is based upon proprietary discoveries of the molecular mechanisms underlying a form of cell death called apoptosis. Apoptos...view more

Market / Customers

CBLI serves two distinct markets or customer groups with its pipeline of drugs: Medical Oncology market providing both potential cancer treatments and supportive care agents; and Defense market, provi......view more

Competitors / Substitutes / Alternatives

In the medical market, competitors for supportive care agents include G-CSF in various forms or other hematological growth factors, or other antiradiation agents such as amifostine or ethyol. In the d...view more